Effect of APOE ɛ4 Status on Brain Amyloid‐β and Cognitive Function in Amnestic and Nonamnestic Mild Cognitive Impairment: A [18F] Florbetapir PET‐CT Study

Abstract

AbstractMild cognitive impairment (MCI) is recognized as a predementia syndrome caused by multiple etiologies and nonmemory symptoms in MCI have recently gained increasing attention. However, the pattern of Aβ deposition and the effect of APOE (apolipoprotein E, APOE) ε4 on cognitive impairment in amnestic MCI (aMCI) and nonamnestic MCI (naMCI) patients has not been demonstrated. In this work, the amyloid‐β (Aβ) load by [18F]florbetapir PET imaging and cognitive performance is compared by comprehensive neuropsychological scales in participants with different MCI types or different APOE ε4 carriage status. According to the Aβ positivity and results of voxel‐wise analysis, higher Aβ loads are observed in aMCI patients than naMCI patients, especially aMCI patients with APOE ε4. Additionally, it is observed that memory domain Z scores show a strong negative correlation with global florbetapir SUVR in the aMCI group (r = – 0.352, p < 0.001) but not in the naMCI group (r = –0.016, p = 0.924). Moreover, this correlation is independent of APOE e4 carriage status. This study aims to identify high‐risk groups at an early stage of AD(Alzheimer's Disease, AD) through cognitive performance and APOE ε4 carrier status, which can be important for guiding clinical intervention trials.